Product: Human medicines
How to implement common Baltic packs for human medicines
28.04.2026
How to write a strong Module 3 for a marketing authorisation application
21.04.2026
Q&A: What to know about EU marketing authorisation variations – procedures, timelines and classification
21.04.2026
Q&A: How is pharmaceutical marketing regulated in Finland? Requirements and compliance issues
15.04.2026
How do post-marketing drug safety practices differ between Japan, the US, and the EU
07.04.2026
Planning a marketing authorisation transfer in the Baltic countries: key considerations
17.03.2026
Maintaining a marketing authorisation in the EU: MAH responsibilities after approval
11.03.2026
What are the MAH’s post-authorisation pharmacovigilance responsibilities
10.03.2026
What does it take to enter the EU pharmaceutical market? Regulatory, supply chain and market access realities explained
27.02.2026








